Issued 2026-08-13 at $29.99 · now $28.89 (2026-08-13, −3.7% since)
Based on its own history, a month from the 2026-08-13 close, VERA has typically landed between $22.13 and $44.20 — a range of −26.2% to +47.4% from the issuance price $29.99.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
1,295 overlapping 1 month windows · 2021-05-14 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($29.99) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where VERA has typically landed a month from the 2026-08-13 close of $29.99 — the range is history, not a prediction.
- now $28.89 (-3.7%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $29.64 (-1.2%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $25.56–$33.71
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $22.13–$44.2
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2022-12-06 | −67.5% | −67.5% | +23.3% |
| 2022-12-05 | −66.2% | −66.2% | +26.7% |
| 2022-12-02 | −65.6% | −65.6% | +25.8% |
| 3 best | |||
| 2024-01-18 | +208.2% | +0.0% | +208.2% |
| 2024-01-19 | +199.3% | +0.0% | +207.8% |
| 2024-01-17 | +190.6% | −4.8% | +190.6% |
1,295 overlapping windows · 2021-05-14 – 2026-08-13 · not cherry-picked
Pending catalysts
- September 2026 — Trial primary completion: Phase 2 primary completion: Monthly Dosing of Atacicept in IgAN (source, as of 2026-08-14)
- November 2027 — Trial primary completion: Phase 2 primary completion: Atacicept in Multiple Glomerular Diseases (source, as of 2026-08-14)
- 2031-05-21 — Trial primary completion: Phase 2 primary completion: A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~6 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.